ReviewFrontiers in oncology2022

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents.

Zhen-Hao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.